/C O R R E C T I O N -- Abbott Laboratories/
01 Novembre 2004 - 4:00PM
PR Newswire (US)
/C O R R E C T I O N -- Abbott Laboratories/ In the news release,
Longest Study of Kaletra(R) (Lopinavir/Ritonavir) Based Regimen
Demonstrated Favorable Resistance Profile for Patients Through Six
Years of Initial HIV Therapy, issued earlier today by Abbott
Laboratories over PR Newswire, the third paragraph, first sentence
should read "Data from the randomized, uncontrolled, prospective
Phase II study of 100 treatment- naive patients taking Kaletra..."
rather than "...100 treatment-naove patients taking Kaletra..." as
incorrectly transmitted by PR Newswire. PRNewswire -- Nov. 1
DATASOURCE: Abbott Laboratories Web site: http://www.abbott.com/
Company News On-Call: http://www.prnewswire.com/comp/110328.html
Copyright